Ibustrin

Indobufen, the active ingredient in Ibustrin, is an antiplatelet agent presented as an oral formulation for systemic use. It is employed to reduce platelet aggregation and thereby helps prevent arterial clot formation in patients at risk of cardiovascular events.

GNH USA supplies Ibustrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ibustrin is an antiplatelet drug used in the management of arterial thrombotic conditions.

- Arterial thromboembolic events: lowers the risk of clot formation in arteries. - Post‑myocardial infarction: provides secondary prevention of recurrent heart attacks. - High‑risk stroke patients: helps prevent ischemic stroke in individuals with elevated risk. - Peripheral arterial disease: improves blood flow by reducing platelet aggregation in peripheral vessels.

Adverse reactions may occur with any antiplatelet therapy.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia, or abdominal pain. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Minor bleeding: such as gum or nasal bleeding.

Serious or Rare Side Effects: - Severe gastrointestinal bleeding or ulceration. - Intracranial hemorrhage. - Allergic reactions: rash, pruritus, or anaphylaxis. - Hematuria or other unexplained bleeding. - Thrombocytopenia: low platelet count.

Use Ibustrin with caution in patients at increased risk of bleeding or with certain medical conditions.

- Bleeding risk: monitor for signs of hemorrhage, especially gastrointestinal or intracranial bleeding. - Renal impairment: adjust therapy and monitor renal function regularly. - Hepatic disease: assess liver function before initiating treatment. - Concomitant anticoagulants: avoid combined use unless clinically justified. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Indobufen may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other antiplatelet agents (e.g., clopidogrel, aspirin): increased bleeding risk. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): additive anticoagulant effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: may potentiate bleeding tendencies. - CYP2C9 inhibitors (e.g., fluconazole): possible increase in indobufen plasma levels. - ACE inhibitors or ARBs: monitor blood pressure and renal function.